| Monday, October 20, 2014, Day One |
| 10:00 - 11:30 AM |
Attendees are invited to move from room-to-room |
| Room |
|
|
| Session Title |
TRA-1. CONCURRENT PRESENTATIONS OF TOP RATED ABSTRACTS I: PREFERENCE AND DECISION MAKING
Click to view session |
TRA-2. CONCURRENT PRESENTATIONS OF TOP RATED ABSTRACTS II: MODELING AND POPULATION HEALTH
Click to view session |
| 10:00 - 10:15 |
TRA-1-1* (DEC) SOCIAL NORMATIVE BELIEFS ARE CENTRAL TO..
TRA-1-1* (DEC) SOCIAL NORMATIVE BELIEFS ARE CENTRAL TO PATIENT CHOICE TO INTENSIFY THERAPY IN RHEUMATOID ARTHRITIS
|
TRA-2-1 (AHE) COST-EFFECTIVENESS ANALYSIS OF CYP2B6 GENETIC..
TRA-2-1 (AHE) COST-EFFECTIVENESS ANALYSIS OF CYP2B6 GENETIC TESTING TO INFORM EFAVIRENZ DOSE REDUCTION FOR INITIAL HIV THERAPY
|
| 10:15 - 10:30 |
TRA-1-2* (DEC) TRANSPARENCY ABOUT BENEFITS AND HARMS IS..
TRA-1-2* (DEC) TRANSPARENCY ABOUT BENEFITS AND HARMS IS UNCOMMON IN RECOMMENDATIONS ON CANCER SCREENING & PREVENTION
|
TRA-2-2 (HSP) VARIABILITY IN REVASCULARIZATION TREATMENT..
TRA-2-2 (HSP) VARIABILITY IN REVASCULARIZATION TREATMENT DECISIONS AMONG HOSPITALS AND ITS ASSOCIATION WITH SURGICAL MORTALITY
|
| 10:30 - 10:45 |
TRA-1-3 (DEC) USING CONJOINT ANALYSIS TO ASSESS THE RELATIVE..
TRA-1-3 (DEC) USING CONJOINT ANALYSIS TO ASSESS THE RELATIVE INFLUENCE OF RESUSCITATION PREFERENCES ON OBSTETRICAL MANAGEMENT OF PERIVIABLE DELIVERIES
|
TRA-2-3 (MET) A NOVEL BIVARIATE BETA DISTRIBUTION CONSTRUCTE..
TRA-2-3 (MET) A NOVEL BIVARIATE BETA DISTRIBUTION CONSTRUCTED FROM THE DIRICHLET DISTRIBUTION
|
| 10:45 - 11:00 |
TRA-1-4 (DEC) HOW PATIENTS' PRIMARY TREATMENT CHOICES FOR..
TRA-1-4 (DEC) HOW PATIENTS' PRIMARY TREATMENT CHOICES FOR LOCALIZED PROSTATE CANCER SHIFT WITH PATIENTS' DIFFERENT PREFERENCES ON SIDE EFFECTS
|
TRA-2-4 (MET) A PROGRESSIVE CALIBRATION PROCEDURE FOR..
TRA-2-4 (MET) A PROGRESSIVE CALIBRATION PROCEDURE FOR INDIVIDUALIZED COLORECTAL CANCER SCREENING STUDY
|
| 11:00 - 11:15 |
TRA-1-5 (PFA) WHERE PATIENTS STAND DEPENDS ON WHERE THEY..
TRA-1-5 (PFA) WHERE PATIENTS STAND DEPENDS ON WHERE THEY SIT: CURRENT HEALTH STATUS AND TOLERANCE FOR THERAPEUTIC RISKS
|
TRA-2-5 (MET) *TOP RANKED ABSTRACT AT THE 15TH BIENNIAL..
TRA-2-5 (MET) *TOP RANKED ABSTRACT AT THE 15TH BIENNIAL EUROPEAN MEETING* COMBINING MARKOV STATES: A COMPARISON OF ANALYTICAL AND HEURISTIC METHODS FOR DERIVING THE HAZARD RATES OF A COLLAPSED MARKOV STATE
|
| 11:15 - 11:30 |
TRA-1-6 (DEC) *TOP RANKED ABSTRACT AT THE 2014 ASIA -..
TRA-1-6 (DEC) *TOP RANKED ABSTRACT AT THE 2014 ASIA - PACIFIC CONFERENCE* CONCORDANCE IN PREFERENCES FOR END OF LIFE CARE BETWEEN ADVANCED CANCER PATIENTS AND THEIR CAREGIVERS IN SINGAPORE: A DISCRETE CHOICE EXPERIMENT
|
TRA-2-6 (PFA) CHANGES IN HEALTH-RELATED QUALITY OF LIFE..
TRA-2-6 (PFA) CHANGES IN HEALTH-RELATED QUALITY OF LIFE AMONG CANCER SURVIVORS: A POPULATION ANALYSIS
|
| 1:00 - 2:30 PM |
Attendees are invited to move from room-to-room |
| Room |
|
|
|
| Session Title |
1A. ESTIMATING & APPLYING COSTS: AN INTERNATIONAL SESSION
Click to view session |
1B. PREFERENCE ASSESSMENT AND OTHER EVALUATION METHODS
Click to view session |
1C. COST ANALYSES AND CLINICAL PRACTICE
Click to view session |
| 1:00 - 1:15 |
1A-1 (AHE) ESTIMATING INDIVIDUAL MEDICAL EXPENDITURES..
1A-1 (AHE) ESTIMATING INDIVIDUAL MEDICAL EXPENDITURES FROM HOUSEHOLD SURVEYS IN THE CONTEXT OF URBANIZATION AND ECONOMIC DEVELOPMENT: INDIA, 1995-2010
|
1B-1 (PFA) THE VALUE OF FAME AND SHAME: DRUG-DIVERSION..
1B-1 (PFA) THE VALUE OF FAME AND SHAME: DRUG-DIVERSION INCENTIVES AND DISINCENTIVES IN SPORT
|
1C-1 (HSP) PRICING IN THE MARKET FOR ANTICANCER DRUGS
1C-1 (HSP) PRICING IN THE MARKET FOR ANTICANCER DRUGS
|
| 1:15 - 1:30 |
1A-2 (AHE) ESTIMATING THE COSTS ASSOCIATED WITH..
1A-2 (AHE) ESTIMATING THE COSTS ASSOCIATED WITH MENINGOCOCCAL OUTBREAKS IN BRAZIL AND COLOMBIA
|
1B-2 (PFA) VALUING PREFERENCES FOR THE PROCESS AND..
1B-2 (PFA) VALUING PREFERENCES FOR THE PROCESS AND OUTCOME OF CLINICAL GENETICS SERVICES: A PILOT STUDY
|
1C-2 (HSP) PATTERNS OF COST-RELATED MEDICATION NON-ADHERE..
1C-2 (HSP) PATTERNS OF COST-RELATED MEDICATION NON-ADHERENCE AMONG OLDER PATIENTS AT HIGH RISK OF HOSPITALIZATION
|
| 1:30 - 1:45 |
1A-3 (AHE) COST EFFECTIVENESS OF THE NEW MEDICINE SERVICE..
1A-3 (AHE) COST EFFECTIVENESS OF THE NEW MEDICINE SERVICE IN COMMUNITY PHARMACIES IN ENGLAND
|
1B-3 (PFA) MODELING INDIVIDUAL UTILITY FROM COLORECTAL..
1B-3 (PFA) MODELING INDIVIDUAL UTILITY FROM COLORECTAL CANCER SCREENING
|
1C-3 (HSP) ASSESSING THE PERFORMANCE OF ART DELIVERY: A..
1C-3 (HSP) ASSESSING THE PERFORMANCE OF ART DELIVERY: A COSTS EFFICIENCY ANALYSIS OF THE MEXICAN HIV PROGRAM
|
| 1:45 - 2:00 |
1A-4 (AHE) ANALYSIS OF HEALTHCARE COSTS IN PATIENTS WITH..
1A-4 (AHE) ANALYSIS OF HEALTHCARE COSTS IN PATIENTS WITH ACUTE WHIPLASH-ASSOCIATED DISORDERS USING ZERO-ADJUSTED GAMMA MODELS
|
1B-4 (PFA) A FRAMEWORK FOR DIFFERENTIATING BETWEEN HEALTH..
1B-4 (PFA) A FRAMEWORK FOR DIFFERENTIATING BETWEEN HEALTH IMPROVEMENTS AND IMPAIRMENTS IN QALY-ANALYSES
|
1C-4 (HSP) COGNITIVE INERTIA AND TECHNOLOGICAL ABANDONMEN..
1C-4 (HSP) COGNITIVE INERTIA AND TECHNOLOGICAL ABANDONMENT IN MEDICINE
|
| 2:00 - 2:15 |
1A-6 (AHE) DYNAMICS IN THE COSTS OF CRIMINALITY AMONG..
1A-6 (AHE) DYNAMICS IN THE COSTS OF CRIMINALITY AMONG OPIOID DEPENDENT INDIVIDUALS
|
1B-5 (PFA) EMPIRICAL EVALUATION OF THE ACCEPTABLE REGRET..
1B-5 (PFA) EMPIRICAL EVALUATION OF THE ACCEPTABLE REGRET MODEL OF MEDICAL DECISION- MAKING
|
1C-5 (MET) SYSTEMATICALLY-DEVELOPED GUIDANCE FOR THE..
1C-5 (MET) SYSTEMATICALLY-DEVELOPED GUIDANCE FOR THE CONDUCT AND REPORTING OF DECISION AND SIMULATION MODELS
|
| 2:15 - 2:30 |
|
1B-6 (PFA) BEST-WORST SCALING ALLOWS US TO QUANTIFY..
1B-6 (PFA) BEST-WORST SCALING ALLOWS US TO QUANTIFY ATTITUDES AS WELL AS PREFERENCES; RESPONSE TIMES TELL US WHICH ARE "GUT" ATTITUDES WITH NO PREDICTIVE POWER
|
1C-6 (MET) WHOSE QALYS COUNT IN COST-EFFECTIVENESS..
1C-6 (MET) WHOSE QALYS COUNT IN COST-EFFECTIVENESS ANALYSES? EVALUATING INTERVENTIONS THAT AFFECT FERTILITY AND CHILDBEARING
|
| 4:15 - 5:30 PM |
Attendees are invited to move from room-to-room |
| Room |
|
|
|
| Session Title |
2D. THEORETICAL ADVANCES IN MODELING METHODS
Click to view session |
2E. VACCINES: DECISION MAKING, POLICY, AND CLINICAL TRIALS
Click to view session |
2F. BREAST CANCER: DECISION MAKING, COSTS, AND POLICY
Click to view session |
| 4:15 - 4:30 |
2D-1 (MET) HANDLING MISSING DATA IN META-ANALYSIS OF..
2D-1 (MET) HANDLING MISSING DATA IN META-ANALYSIS OF INDIVIDUAL PARTICIPANT DATA WITH MIXED OUTCOMES
|
2E-1 (DEC) PARENTAL RISK PERCEPTION AND DECISION MAKING..
2E-1 (DEC) PARENTAL RISK PERCEPTION AND DECISION MAKING REGARDING VACCINATION OF THEIR ELIGIBLE CHILDREN WITH THE HUMAN PAPILLOMAVIRUS VACCINE
|
2F-1 (HSP) COST AND POLICY IMPLICATIONS OF ADOPTION OF..
2F-1 (HSP) COST AND POLICY IMPLICATIONS OF ADOPTION OF NEW RADIOTHERAPY TECHNOLOGY FOR BREAST CANCER
|
| 4:30 - 4:45 |
2D-2 (MET) EVALUATING DIFFERENT APPROACHES TO ESTIMATING..
2D-2 (MET) EVALUATING DIFFERENT APPROACHES TO ESTIMATING TREATMENT COSTS FROM A RANDOMIZED CLINICAL TRIAL WITH INCOMPLETE FOLLOW-UP
|
2E-2 (DEC) WELL-DESIGNED RISK COMMUNICATION AND VALUES..
2E-2 (DEC) WELL-DESIGNED RISK COMMUNICATION AND VALUES CLARIFICATION METHODS IMPROVE PARENTS' DECISIONS ABOUT INFLUENZA VACCINES FOR THEIR CHILDREN
|
2F-2 (HSP) FACTORS ASSOCIATED WITH DECISIONS FOR..
2F-2 (HSP) FACTORS ASSOCIATED WITH DECISIONS FOR CONTRALATERAL PROPHYLACTIC MASTECTOMY
|
| 4:45 - 5:00 |
2D-3 (MET) THE IMPACT OF ESTIMATING MORTALITY RATES IN..
2D-3 (MET) THE IMPACT OF ESTIMATING MORTALITY RATES IN COST-EFFECTIVENESS ANALYSIS.: A SIMULATION STUDY
|
2E-3 (DEC) JOURNEY TO VACCINATION: A QUALITATIVE..
2E-3 (DEC) JOURNEY TO VACCINATION: A QUALITATIVE EXPLORATION OF HOW BELIEFS, PERCEPTIONS AND PREVIOUS EXPERIENCES INFLUENCE VACCINATION BEHAVIOR
|
2F-3 (DEC) EXPLAINING THE EFFICACY OF THE BRCA GIST..
2F-3 (DEC) EXPLAINING THE EFFICACY OF THE BRCA GIST INTELLIGENT TUTOR FOR GENETIC TESTING AND BREAST CANCER RISK
|
| 5:00 - 5:15 |
2D-4 (MET) RESOLVING STRUCTURAL BIAS DUE TO COMMON RANDOM..
2D-4 (MET) RESOLVING STRUCTURAL BIAS DUE TO COMMON RANDOM NUMBERS WHEN SIMULATING EVENTS WITH NON-ORDERED OUTCOMES
|
2E-4 (HSP) RELATIVE BENEFITS ON HOSPITALIZATION AND..
2E-4 (HSP) RELATIVE BENEFITS ON HOSPITALIZATION AND AVERTED HOSPITALIZATION COSTS OF LIVE ATTENUATED INFLUENZA VACCINE (LAIV) PREFERENTIAL POLICY FOR CHILDREN, AGES 2-8
|
2F-4 (DEC) BREAST CANCER PATIENTS' INVOLVEMENT IN..
2F-4 (DEC) BREAST CANCER PATIENTS' INVOLVEMENT IN DECISIONS: PERSPECTIVE AND TYPE OF ADJUVANT THERAPY MATTER
|
| 5:15 - 5:30 |
2D-5 (MET) THEORETICAL FOUNDATION AND PRACTICAL..
2D-5 (MET) THEORETICAL FOUNDATION AND PRACTICAL APPLICATIONS OF HALF-CYCLE CORRECTION METHODS
|
2E-5 (HSP) A 2-YEAR RANDOMIZED CLUSTER TRIAL TO IMPROVE..
2E-5 (HSP) A 2-YEAR RANDOMIZED CLUSTER TRIAL TO IMPROVE CHILDHOOD INFLUENZA VACCINATION
|
2F-5 (DEC) THE IMPACT OF BREAST CANCER AWARENESS..
2F-5 (DEC) THE IMPACT OF BREAST CANCER AWARENESS ADVERTISEMENTS ON WOMEN'S SELF-OBJECTIFICATION AND HEALTH BEHAVIOR
|
| Tuesday, October 21, 2014, Day Two |
| 10:30 - 12:00 PM |
Attendees are invited to move from room-to-room |
| Room |
|
|
|
| Session Title |
3G. COST EFFECTIVENESS IN CANCER AND CHRONIC CONDITIONS
Click to view session |
3H. RISK COMMUNICATION AND DECISION SUPPORT
Click to view session |
3I. LARGE DATA BASE ANALYSIS AND HEALTH CARE UTILIZATION
Click to view session |
| 10:30 - 10:45 |
3G-1 (AHE) COST-EFFECTIVENESS ANALYSIS OF PALLIATIVE TEAM..
3G-1 (AHE) COST-EFFECTIVENESS ANALYSIS OF PALLIATIVE TEAM CARE FOR PATIENTS NEARING END-OF-LIFE
|
3H-1 (DEC) USE OF PATIENT DECISION AIDS IN ROUTINE CARE:..
3H-1 (DEC) USE OF PATIENT DECISION AIDS IN ROUTINE CARE: WHAT IMPACT DOES IT HAVE ON DECISION MAKING ABOUT PROSTATE CANCER SCREENING?
|
3I-1 (HSP) REGIONALIZATION OF HIGH RISK SURGERIES AND ITS..
3I-1 (HSP) REGIONALIZATION OF HIGH RISK SURGERIES AND ITS IMPLICATION ON OUTCOME AND SURGICAL CARE SUPPLY REGULATION
|
| 10:45 - 11:00 |
3G-2 (AHE) DNA PLOIDY ANALYSIS IS A COST-EFFECTIVE..
3G-2 (AHE) DNA PLOIDY ANALYSIS IS A COST-EFFECTIVE ALTERNATIVE FOR CERVICAL SCREENING
|
3H-2 (DEC) CANCELLED: DOES ANIMATION IMPROVE COMPREHENSIO..
3H-2 (DEC) CANCELLED: DOES ANIMATION IMPROVE COMPREHENSION OF RISK INFORMATION IN PATIENTS WITH LOW HEALTH LITERACY?
|
3I-2 (HSP) GEOGRAPHIC VARIATION IN RESPONSE TO FDA..
3I-2 (HSP) GEOGRAPHIC VARIATION IN RESPONSE TO FDA WARNINGS: EVIDENCE FROM A NATIONALLY INTEGRATED SYSTEM
|
| 11:00 - 11:15 |
3G-3 (AHE) WHEN IS ENOUGH EVIDENCE ENOUGH? VALUE-OF-INFOR..
3G-3 (AHE) WHEN IS ENOUGH EVIDENCE ENOUGH? VALUE-OF-INFORMATION ANALYSIS FOR PRIORITIZING ADDITIONAL OUTCOMES RESEARCH ON THE TREATMENT OF CHRONIC MYELOID LEUKEMIA
|
3H-3 (DEC) USING A WEB-BASED PATIENT REPORTED OUTCOMES..
3H-3 (DEC) USING A WEB-BASED PATIENT REPORTED OUTCOMES TOOL (MYPSYCKES) TO ASSESS MENTAL HEALTH PATIENTS' INTEREST IN ALTERNATIVE THERAPIES AND RELATED CONCERNS
|
3I-3 (HSP) DOES OBESITY PLAY A ROLE IN THE DEVELOPMENT OF..
3I-3 (HSP) DOES OBESITY PLAY A ROLE IN THE DEVELOPMENT OF MULTIPLE MYELOMA IN PATIENTS WITH MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE: USING DATA FROM THE UNITED STATES VETERANS HEALTH ADMINISTRATION HOSPITAL SYSTEM?
|
| 11:15 - 11:30 |
3G-4 (AHE) ERLOTINIB, AFATINIB, AND CISPLATIN/PEMETREXED..
3G-4 (AHE) ERLOTINIB, AFATINIB, AND CISPLATIN/PEMETREXED FOR FIRST-LINE TREATMENT OF ADVANCED EGFR-MUTATION POSITIVE NON-SMALL CELL LUNG CANCER: VALUE-OF-INFORMATION ANALYSIS
|
3H-4 (DEC) USING EXPERIENCE NARRATIVES TO REDUCE..
3H-4 (DEC) USING EXPERIENCE NARRATIVES TO REDUCE AFFECTIVE FORECASTING ERRORS
|
3I-4 (HSP) BEYOND SEQUENCING FOR MEDICAL PRACTICE PATTERN..
3I-4 (HSP) BEYOND SEQUENCING FOR MEDICAL PRACTICE PATTERN ANALYSIS: THE USE OF HIERARCHICAL CLUSTER ANALYSIS WITH AN APPLICATION TO URETEROLITHIASIS
|
| 11:30 - 11:45 |
3G-5 (AHE) PATIENT-CENTERED SURVEILLANCE STRATEGIES FOR..
3G-5 (AHE) PATIENT-CENTERED SURVEILLANCE STRATEGIES FOR HEPATOCELLULAR CARCINOMA: A SOCIETAL PERSPECTIVE
|
3H-5 (DEC) A TAILORED APPROACH TO RISK COMMUNICATION IN..
3H-5 (DEC) A TAILORED APPROACH TO RISK COMMUNICATION IN DECISION AIDS: FINDING THE OPTIMAL FORMAT FOR INDIVIDUALS
|
3I-5 (HSP) USE OF CLINICAL PATHWAYS RESULTED IN LOWER..
3I-5 (HSP) USE OF CLINICAL PATHWAYS RESULTED IN LOWER IMAGING RATES FOR A MEDICARE POPULATION
|
| 11:45 - 12:00 |
3G-6 (AHE) COST-EFFECTIVENESS ANALYSIS OF METASTATIC..
3G-6 (AHE) COST-EFFECTIVENESS ANALYSIS OF METASTATIC BREAST CANCER TREATMENTS: A STUDY BASED ON THE BOLERO-2 TRIAL
|
3H-6 (DEC) EFFECTIVENESS OF COMPUTERIZED WEIGHT..
3H-6 (DEC) EFFECTIVENESS OF COMPUTERIZED WEIGHT MANAGEMENT WITH PEER SUPPORTS FOR PEOPLE WITH MENTAL ILLNESS
|
3I-6 (HSP) DISCONTINUATION, RESTART, AND SWITCHING..
3I-6 (HSP) DISCONTINUATION, RESTART, AND SWITCHING PATTERNS AMONG PSORIASIS PATIENTS TREATED WITH ADALIMUMAB, ETANERCEPT OR USTEKINUMAB: A UNITED STATES CLAIMS DATABASE ANALYSIS
|
| 3:30 - 5:00 PM |
Attendees are invited to move from room-to-room |
| Room |
|
|
|
| Session Title |
4J. HEART DISEASE: DECISION MAKING AND CLINICAL GUIDELINE IMPLEMENTATION
Click to view session |
4K. MEASUREMENT AND EXPECTATIONS
Click to view session |
4L. COMPARATIVE EFFECTIVENESS RESEARCH
Click to view session |
| 3:30 - 3:45 |
4J-1 (MET) ELICITING LIPID MANAGEMENT GUIDELINES'..
4J-1 (MET) ELICITING LIPID MANAGEMENT GUIDELINES' VALUATION OF FUTURE LIFE
|
4K-1 (HSP) COMPREHENSIVELY MEASURING SUBJECTIVE..
4K-1 (HSP) COMPREHENSIVELY MEASURING SUBJECTIVE WELL-BEING: DIMENSIONALITY ANALYSIS FOR IMPROVED OUTCOME ASSESSMENT
|
4L-1 (DEC) PRESENTING STOOL TESTING AS THE DEFAULT OPTION..
4L-1 (DEC) PRESENTING STOOL TESTING AS THE DEFAULT OPTION FOR COLORECTAL CANCER SCREENING: RESULTS OF A RANDOMIZED TRIAL
|
| 3:45 - 4:00 |
4J-2 (HSP) THE PAY-OFF TIME FRAMEWORK: AN APPLICATION TO..
4J-2 (HSP) THE PAY-OFF TIME FRAMEWORK: AN APPLICATION TO A NATIONAL CLINICAL GUIDELINE ON HYPERTENSION
|
4K-2 (DEC) UNCERTAINTY ABOUT EFFECTS IS A KEY FACTOR..
4K-2 (DEC) UNCERTAINTY ABOUT EFFECTS IS A KEY FACTOR INFLUENCING INSTITUTIONAL REVIEW BOARDS' APPROVAL OF CLINICAL STUDIES
|
4L-2 (HSP) EXPLORING THE EFFECTS OF FACTORS ASSOCIATED..
4L-2 (HSP) EXPLORING THE EFFECTS OF FACTORS ASSOCIATED WITH THE OUTCOME OF PANCREATIC CANCER SCREENING IN HIGH-RISK INDIVIDUALS BY THE USE OF A MICROSIMULATION MODEL
|
| 4:00 - 4:15 |
4J-3 (HSP) AUTOMATING IDENTIFICATION OF MULTIPLE CHRONIC..
4J-3 (HSP) AUTOMATING IDENTIFICATION OF MULTIPLE CHRONIC CONDITIONS IN CLINICAL PRACTICE GUIDELINE RECOMMENDATIONS
|
4K-3 (DEC) DEVELOPMENT OF A MEDICAL MAXIMIZER SCALE
4K-3 (DEC) DEVELOPMENT OF A MEDICAL MAXIMIZER SCALE
|
4L-3 (DEC) PREVALENCE OF CLINICAL GUIDELINE-DIRECTED..
4L-3 (DEC) PREVALENCE OF CLINICAL GUIDELINE-DIRECTED TREATMENT INTENSIFICATION IN DIABETES MELLITUS: A SYSTEMATIC REVIEW
|
| 4:15 - 4:30 |
4J-4 (HSP) META-ANALYSIS OF PREFERENCE-BASED QUALITY OF..
4J-4 (HSP) META-ANALYSIS OF PREFERENCE-BASED QUALITY OF LIFE VALUES IN CORONARY HEART DISEASE
|
4K-4 (DEC) PARENTS BURDEN OF PEDIATRIC INFLUENZA AS A..
4K-4 (DEC) PARENTS BURDEN OF PEDIATRIC INFLUENZA AS A CAREGIVER AND THEIR EXPECTATION TO RECEIVE ANTIBIOTIC PRESCRIPTIONS FOR THEIR CHILDREN – A PILOT STUDY AT A PEDIATRIC CLINIC
|
4L-4 (HSP) OPTIMAL COLORECTAL CANCER SCREENING FOR A..
4L-4 (HSP) OPTIMAL COLORECTAL CANCER SCREENING FOR A HIGHER-RISK POPULATION: THE CASE OF NORTHEASTERN PENNSYLVANIA
|
| 4:30 - 4:45 |
4J-5 (DEC) PATIENTS' FUTURE EXPECTATIONS ABOUT DIABETES..
4J-5 (DEC) PATIENTS' FUTURE EXPECTATIONS ABOUT DIABETES AND HYPERTENSION: THE ON TIME STUDY
|
4K-5 (DEC) PERCEPTION OF SURGICAL SITE INFECTION RISK..
4K-5 (DEC) PERCEPTION OF SURGICAL SITE INFECTION RISK FACTORS FOR SPINE SURGERY VARIES BY OPERATIVE TEAM ROLE
|
4L-5 (HSP) CLINICAL DECISION RULES UBIQUITOUS TO THE..
4L-5 (HSP) CLINICAL DECISION RULES UBIQUITOUS TO THE EMERGENCY CARE SETTING ARE NOT EFFECTIVE IN RESOLVING THE BURDEN OF UNNECESSARY CT IMAGING IN WOMEN EVALUATED FOR PULMONARY EMBOLISM
|
| 4:45 - 5:00 |
4J-6 (HSP) COMORBIDITIES IN HEART FAILURE CAN GUIDE..
4J-6 (HSP) COMORBIDITIES IN HEART FAILURE CAN GUIDE TREATMENT OPTIONS
|
4K-6 (DEC) MEASURING FEAR OF "BEING THE 1": EMOTIONAL..
4K-6 (DEC) MEASURING FEAR OF "BEING THE 1": EMOTIONAL REACTIVITY TO THE POSSIBILITY (NOT PROBABILITY) OF RISK
|
(HSP) IMPLEMENTATION CHALLENGES OF A COMMUNITY-BASED..
(HSP) IMPLEMENTATION CHALLENGES OF A COMMUNITY-BASED PRAGMATIC RANDOMIZED CONTROLLED TRIAL IN WOUND CARE
|
| Wednesday, October 22, 2014, Day Three |
| 10:00 - 11:30 AM |
Attendees are invited to move from room-to-room |
| Room |
|
|
|
| Session Title |
5M. USING MODELING TO IMPROVE RESOURCE ALLOCATION
Click to view session |
5N. DECISION MODELING
Click to view session |
5O. CLINICAL DECISION MAKING
Click to view session |
| 10:00 - 10:15 |
5M-1 (AHE) IN VITRO FERTILIZATION INSURANCE COVERAGE AND..
5M-1 (AHE) IN VITRO FERTILIZATION INSURANCE COVERAGE AND CHANCES OF A LIVE BIRTH
|
5N-1 (MET) A DYNAMIC DECISION MODEL TO IDENTIFY..
5N-1 (MET) A DYNAMIC DECISION MODEL TO IDENTIFY COST-EFFECTIVE POLICIES FOR CONTROLLING EPIDEMICS
|
5O-1 (DEC) INFERTILITY-RELATED DECISION MAKING AND..
5O-1 (DEC) INFERTILITY-RELATED DECISION MAKING AND DECISIONAL CONFLICT
|
| 10:15 - 10:30 |
5M-2 (AHE) MODELING THE COST EFFECTIVENESS OF NEUROIMAGIN..
5M-2 (AHE) MODELING THE COST EFFECTIVENESS OF NEUROIMAGING-BASED TREATMENT OF ACUTE STROKE PATIENTS WITH UNKNOWN STROKE ONSET TIME
|
5N-2 (MET) STRATEGIES TO PREEMPTIVELY GENOTYPE PATIENTS..
5N-2 (MET) STRATEGIES TO PREEMPTIVELY GENOTYPE PATIENTS FOR INDIVIDUALIZED MEDICINE
|
5O-2 (DEC) IMPROVING PHYSICIAN DECISION-MAKING TO REDUCE..
5O-2 (DEC) IMPROVING PHYSICIAN DECISION-MAKING TO REDUCE RISK EXPOSURE
|
| 10:30 - 10:45 |
5M-3 (AHE) COST-EFFECTIVENESS OF DIAGNOSTIC TESTS FOR..
5M-3 (AHE) COST-EFFECTIVENESS OF DIAGNOSTIC TESTS FOR ASSESSING STABLE CHEST PAIN: SHOULD CARDIAC MAGNETIC RESONANCE AND CORONARY COMPUTED TOMOGRAPHY BE REIMBURSED BY A MIDDLE-INCOME COUNTRY'S PUBLIC HEALTHCARE SYSTEM?
|
5N-3 (MET) THE ONCOTYROL PROSTATE CANCER OUTCOME AND..
5N-3 (MET) THE ONCOTYROL PROSTATE CANCER OUTCOME AND POLICY MODEL - LESSONS LEARNED FROM NATURAL HISTORY CALIBRATION
|
5O-3 (HSP) DEVELOPING AND EVALUATING A WEB-BASED PATIENT..
5O-3 (HSP) DEVELOPING AND EVALUATING A WEB-BASED PATIENT REPORTED OUTCOMES AND DECISION SUPPORT TOOL (MYPSYCKES)
|
| 10:45 - 11:00 |
5M-4 (AHE) HEPATITIS C PREVENTION BY SCREENING AND..
5M-4 (AHE) HEPATITIS C PREVENTION BY SCREENING AND TREATMENT IN UNITED STATES PRISONS: AN AGENT-BASED APPROACH
|
5N-4 (MET) DYNAMIC NETWORK DISEASE MODELING OF THE..
5N-4 (MET) DYNAMIC NETWORK DISEASE MODELING OF THE SYNERGISTIC TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS AND HERPES SIMPLEX VIRUS 2
|
5O-4 (HSP) DOES COLOR-HIGHLIGHTING CLINICAL DECISION..
5O-4 (HSP) DOES COLOR-HIGHLIGHTING CLINICAL DECISION SUPPORT REMINDERS IMPROVE PHYSICIANS' RESPONSIVENESS?
|
| 11:00 - 11:15 |
5M-5 (AHE) COSTS AND OUTCOMES OF FIVE SURGICAL TREATMENTS..
5M-5 (AHE) COSTS AND OUTCOMES OF FIVE SURGICAL TREATMENTS FOR GREAT SAPHENOUS VARICOSE VEINS: HIGH LIGATION AND STRIPPING, LASER ABLATION, RADIOFREQUENCY ABLATION, STEAM VEIN SCLEROSIS AND CYANOACRYLATE GLUE
|
5N-5 (MET) INCORPORATION OF PATIENT COLONIZATION WITH..
5N-5 (MET) INCORPORATION OF PATIENT COLONIZATION WITH VANCOMYCIN-RESISTANT ENTEROCOCCUS (VRE) AND METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) AND PATIENT ACUITY INTO A DISCRETE EVENT SIMULATION MODEL OF INPATIENT BED ALLOCATION AND PATIENT FLOW
|
5O-5 (DEC) PATIENT-SPECIFIC PHARMACOGENOMIC RESULTS..
5O-5 (DEC) PATIENT-SPECIFIC PHARMACOGENOMIC RESULTS DELIVERED VIA A GENOMIC PRESCRIBING DECISION SUPPORT SYSTEM STRONGLY INFLUENCE PHYSICIAN MEDICATION DECISION-MAKING AND PRESCRIBING BEHAVIORS
|
| 11:15 - 11:30 |
|
5N-6 (MET) COST-EFFECTIVENESS ANALYSES THAT USE..
5N-6 (MET) COST-EFFECTIVENESS ANALYSES THAT USE RANDOMIZED TRIALS: INSTRUMENTAL VARIABLE APPROACHES FOR HANDLING NON-COMPLIANCE
|
5O-6 (DEC) PERSPECTIVE INSTRUCTIONS TO INCREASE STUDENT..
5O-6 (DEC) PERSPECTIVE INSTRUCTIONS TO INCREASE STUDENT EMPATHY IN MEDICAL DECISION MAKING
|
